Legal Proceedings.
−Removed: On April 14, 2017, representatives for the estate of a deceased
−Removed: individual filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company, Harvard Bioscience
−Removed: and other defendants.
−Removed: The complaint alleges that the decedent’s injury and death were caused by two tracheal implants that
−Removed: incorporated synthetic trachea scaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically
−Removed: implanted in the decedent in two surgeries performed in 2012 and 2013.
−Removed: The civil complaint seeks a non-specific sum of money to
−Removed: compensate the plaintiffs.
−Removed: This civil lawsuit relates to the Company’s first-generation trachea scaffold technology for which
−Removed: the Company discontinued development in 2014, and not to the Company’s current Cellframe technology nor to its lead development
−Removed: product candidate, the CEI.
−Removed: The litigation is in the discovery stage and the Company intends to vigorously defend this case.
−Removed: the Company believes that such claim lacks merit, the Company is unable to predict the ultimate outcome of such litigation.
−Removed: accordance with a separation and distribution agreement between Harvard Bioscience and the Company relating to the spin-off, the
−Removed: Company would be required to indemnify Harvard Bioscience against losses that Harvard Bioscience may suffer as a result of this
−Removed: The Company has been informed by its insurance provider that the case has been accepted as an insurable claim under
−Removed: the Company’s product liability insurance policy.
−Removed: From time to time, the Company may be involved in various claims
−Removed: and legal proceedings arising in the ordinary course of business.
−Removed: Other than the above matter, there are no such matters pending
−Removed: that the Company expects to be material in relation to its business, financial condition, and results of operations or cash flows.
+Added: On April 14, 2017, representatives for the estate of a deceased individual
+Added: filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company, Harvard Bioscience and other defendants.
+Added: The complaint alleges that the decedent’s injury and death were caused by two tracheal implants that incorporated synthetic trachea
+Added: scaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically implanted in the decedent in two
+Added: surgeries performed in 2012 and 2013.
+Added: The civil complaint seeks a non-specific sum of money to compensate the plaintiffs.
+Added: This civil lawsuit
+Added: relates to the Company’s first-generation trachea scaffold technology for which the Company discontinued development in 2014, and
+Added: not to the Company’s current Cellframe technology nor to its lead development product candidate, the CEI.
+Added: The litigation is in the
+Added: discovery stage and the Company intends to vigorously defend this case.
+Added: While the Company believes that such claim lacks merit, the Company
+Added: is unable to predict the ultimate outcome of such litigation.
+Added: In accordance with a separation and distribution agreement between Harvard
+Added: Bioscience and the Company relating to the spin-off, the Company would be required to indemnify Harvard Bioscience against losses that
+Added: Harvard Bioscience may suffer as a result of this litigation.
+Added: The Company has been informed by its insurance provider that the case has
+Added: been accepted as an insurable claim under the Company’s product liability insurance policy.
+Added: From time to time, the Company may be involved in various claims and
+Added: legal proceedings arising in the ordinary course of business.
+Added: Other than the above matter, there are no such matters pending that the
+Added: Company expects to be material in relation to its business, financial condition, and results of operations or cash flows.
Mine Safety Disclosures.
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.